Impact of Sodium-Glucose Cotransporter-2 Inhibitors on Urolithiasis.
作者信息
Anan Go, Kikuchi Daisuke, Hirose Takuo, Ito Hiroki, Nakayama Shingo, Mori Takefumi
机构信息
Department of Urology, Yotsuya Medical Cube, Tokyo, Japan.
Tohoku Medical and Pharmaceutical University, Faculty of Medicine, Sendai, Japan.
出版信息
Kidney Int Rep. 2023 Feb 3;8(4):925-928. doi: 10.1016/j.ekir.2023.01.034. eCollection 2023 Apr.
Abstract
摘要
相似文献
1
Impact of Sodium-Glucose Cotransporter-2 Inhibitors on Urolithiasis.钠-葡萄糖协同转运蛋白2抑制剂对尿路结石的影响。
Kidney Int Rep. 2023 Feb 3;8(4):925-928. doi: 10.1016/j.ekir.2023.01.034. eCollection 2023 Apr.
2
The effect of preoperative sodium-glucose cotransporter 2 inhibitors on the incidence of perioperative metabolic acidosis: A retrospective cohort study.术前钠-葡萄糖共转运蛋白 2 抑制剂对围手术期代谢性酸中毒发生率的影响：一项回顾性队列研究。
BMC Endocr Disord. 2022 Aug 20;22(1):209. doi: 10.1186/s12902-022-01126-z.
3
The ratio of free triiodothyronine to free thyroxine is regulated differently in patients with type 2 diabetes mellitus treated and not treated with sodium glucose cotransporter 2 inhibitors.在接受和未接受钠-葡萄糖协同转运蛋白2抑制剂治疗的2型糖尿病患者中，游离三碘甲状腺原氨酸与游离甲状腺素的比例调节方式不同。
Diabetes Metab Syndr. 2023 Jan;17(1):102704. doi: 10.1016/j.dsx.2022.102704. Epub 2023 Jan 3.
4
Impact of Sodium-Glucose Cotransporter-2 Inhibitors on Sympathetic Nervous System Activity Detected by Sympathetic Activity Index and LF/HF Ratio in Patients with Type 2 Diabetes Mellitus.钠-葡萄糖协同转运蛋白2抑制剂对2型糖尿病患者交感神经系统活性的影响：通过交感神经活动指数和低频/高频比值检测
Turk Kardiyol Dern Ars. 2022 Sep;50(6):415-421. doi: 10.5543/tkda.2022.22403.
5
Sodium-Glucose Cotransporter Inhibitors for the Treatment of Type 1 Diabetes Mellitus.钠-葡萄糖共转运蛋白抑制剂治疗 1 型糖尿病。
Clin Drug Investig. 2020 Nov;40(11):991-1000. doi: 10.1007/s40261-020-00949-9.
6
Preventive effects of the sodium glucose cotransporter 2 inhibitor tofogliflozin on diethylnitrosamine-induced liver tumorigenesis in obese and diabetic mice.钠-葡萄糖协同转运蛋白2抑制剂托格列净对肥胖和糖尿病小鼠二乙基亚硝胺诱导的肝脏肿瘤发生的预防作用
Oncotarget. 2017 Apr 6;8(35):58353-58363. doi: 10.18632/oncotarget.16874. eCollection 2017 Aug 29.
7
Sodium-glucose Cotransporter Type 2 Inhibitors: A New Insight into the Molecular Mechanisms of Diabetic Nephropathy.钠-葡萄糖共转运蛋白 2 抑制剂：糖尿病肾病分子机制的新见解。
Curr Pharm Des. 2022;28(26):2131-2139. doi: 10.2174/1381612828666220617153331.
8
Management of sodium-glucose cotransporter 2 inhibitors during the perioperative period: A retrospective comparative study.围手术期钠-葡萄糖共转运蛋白 2 抑制剂的管理：一项回顾性对比研究。
J Perioper Pract. 2021 Oct;31(10):391-398. doi: 10.1177/1750458920948693. Epub 2020 Sep 8.
9
Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus.心力衰竭风险分层与钠-葡萄糖共转运蛋白 2 抑制剂在 2 型糖尿病患者中的疗效。
Circulation. 2019 Nov 5;140(19):1569-1577. doi: 10.1161/CIRCULATIONAHA.119.042685. Epub 2019 Aug 31.
10
Safety of sodium-glucose cotransporter 2 inhibitors in Asian type 2 diabetes populations.钠-葡萄糖共转运蛋白 2 抑制剂在亚洲 2 型糖尿病人群中的安全性。
J Diabetes Investig. 2023 Feb;14(2):167-182. doi: 10.1111/jdi.13915. Epub 2022 Oct 19.
引用本文的文献
1
Kidney stones and SGLT2 inhibitors.肾结石与钠-葡萄糖协同转运蛋白2抑制剂
Clin Exp Nephrol. 2025 Jul 2. doi: 10.1007/s10157-025-02729-1.
2
Sodium glucose co-transporter 2 inhibitor prevents nephrolithiasis in non-diabetes by restoring impaired autophagic flux.钠葡萄糖协同转运蛋白2抑制剂通过恢复受损的自噬通量来预防非糖尿病患者的肾结石形成。
EBioMedicine. 2025 Apr;114:105668. doi: 10.1016/j.ebiom.2025.105668. Epub 2025 Mar 25.
3
Empagliflozin in nondiabetic individuals with calcium and uric acid kidney stones: a randomized phase 2 trial.恩格列净用于患有钙和尿酸肾结石的非糖尿病个体：一项随机2期试验。
Nat Med. 2025 Jan;31(1):286-293. doi: 10.1038/s41591-024-03330-x. Epub 2025 Jan 2.
4
SGLT2 Inhibitors and Their Effect on Urolithiasis: Current Evidence and Future Directions.钠-葡萄糖协同转运蛋白2抑制剂及其对尿路结石的影响：当前证据与未来方向
J Clin Med. 2024 Oct 9;13(19):6017. doi: 10.3390/jcm13196017.
5
SGLT2 inhibitors and nephrolithiasis risk: a meta-analysis.钠-葡萄糖协同转运蛋白2抑制剂与肾结石风险：一项荟萃分析。
Nephrol Dial Transplant. 2025 Apr 1;40(4):671-678. doi: 10.1093/ndt/gfae179.
6
Sodium-glucose cotranspor ter 2 (SGLT2) inhibitors in nephrolithiasis: should we "gliflozin" patients with kidney stone disease?钠-葡萄糖共转运蛋白 2（SGLT2）抑制剂在肾结石中的应用：我们是否应该给肾结石患者使用“格列净”？
J Bras Nefrol. 2024 Jul-Sep;46(3):e20230146. doi: 10.1590/2175-8239-JBN-2023-0146en.
7
Thiazide prescriptions are not associated with lower urolithiasis: a Japanese epidemiologic study.噻嗪类药物处方与较低的尿路结石发病率无关：一项日本流行病学研究。
Int Urol Nephrol. 2023 Sep;55(9):2225-2226. doi: 10.1007/s11255-023-03671-5. Epub 2023 Jun 13.
8
In Reply to "Letter Regarding 'Impact of Sodium-Glucose Cotransporter-2 Inhibitors on Urolithiasis'".回复《关于“钠-葡萄糖协同转运蛋白2抑制剂对尿路结石的影响”的信》
Kidney Int Rep. 2023 Mar 28;8(6):1268-1269. doi: 10.1016/j.ekir.2023.03.018. eCollection 2023 Jun.
9
Sodium/Glucose Cotransporter 2 Inhibition and Urolithiasis: The Effect of Urinary pH and Citrate.钠/葡萄糖协同转运蛋白2抑制与尿路结石形成：尿液pH值和柠檬酸盐的影响
Kidney Int Rep. 2023 Mar 24;8(6):1268. doi: 10.1016/j.ekir.2023.02.1094. eCollection 2023 Jun.
本文引用的文献
1
Inhibition of sodium-glucose cotransporter 2 suppresses renal stone formation.抑制钠-葡萄糖共转运蛋白 2 可抑制肾结石形成。
Pharmacol Res. 2022 Dec;186:106524. doi: 10.1016/j.phrs.2022.106524. Epub 2022 Oct 28.
2
Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition?恩格列净与肾结石风险降低：SGLT2 抑制的潜在新作用？
J Clin Endocrinol Metab. 2022 Jun 16;107(7):e3003-e3007. doi: 10.1210/clinem/dgac154.
3
Impact of the SGLT2 inhibitor empagliflozin on urinary supersaturations in kidney stone formers (SWEETSTONE trial): protocol for a randomised, double-blind, placebo-controlled cross-over trial.恩格列净对肾结石形成者尿液过饱和度的影响（SWEETSTONE 试验）：一项随机、双盲、安慰剂对照交叉试验的方案。
BMJ Open. 2022 Mar 14;12(3):e059073. doi: 10.1136/bmjopen-2021-059073.
4
Safety of SGLT2 Inhibitors: A Pharmacovigilance Study from 2013 to 2021 Based on FAERS.钠-葡萄糖协同转运蛋白2抑制剂的安全性：一项基于美国食品药品监督管理局不良事件报告系统（FAERS）的2013年至2021年药物警戒研究
Front Pharmacol. 2021 Dec 20;12:766125. doi: 10.3389/fphar.2021.766125. eCollection 2021.
5
Sodium-glucose cotransporter 2 inhibitors and risk of nephrolithiasis.钠-葡萄糖共转运蛋白 2 抑制剂与肾结石风险。
Diabetologia. 2021 Jul;64(7):1563-1571. doi: 10.1007/s00125-021-05424-4. Epub 2021 Mar 13.
6
The Impact of Glycosylation of Osteopontin on Urinary Stone Formation.骨桥蛋白糖基化对尿石形成的影响。
Int J Mol Sci. 2019 Dec 21;21(1):93. doi: 10.3390/ijms21010093.
7
Nephrolithiasis and sodium-glucose co-transporter-2 (SGLT-2) inhibitors: A meta-analysis of randomized controlled trials.肾结石病和钠-葡萄糖协同转运蛋白-2（SGLT-2）抑制剂：随机对照试验的荟萃分析。
Diabetes Res Clin Pract. 2019 Sep;155:107808. doi: 10.1016/j.diabres.2019.107808. Epub 2019 Aug 8.
8
Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice.长期使用钠-葡萄糖协同转运蛋白2抑制剂达格列净治疗可改善db/db小鼠的葡萄糖稳态和糖尿病肾病。
PLoS One. 2014 Jun 24;9(6):e100777. doi: 10.1371/journal.pone.0100777. eCollection 2014.
9
Diabetes mellitus and the risk of nephrolithiasis.糖尿病与肾结石风险
Kidney Int. 2005 Sep;68(3):1230-5. doi: 10.1111/j.1523-1755.2005.00516.x.
Zotero 插件